Yuki Shundo
Overview
Explore the profile of Yuki Shundo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakatsuka M, Watanabe T, Sakai C, Shundo Y, Watanabe Y, Notsuda H, et al.
Transplant Proc
. 2025 Feb;
57(3):487-490.
PMID: 40016046
Delayed chest closure (DCC) is a useful technique in cases with oversized lung grafts, pulmonary edema, and hemodynamic instability. Anatomically oversized lung grafts are potentially problematic in pediatric living-donor lobar...
2.
Chen M, Yanagihara T, Kushima N, Ikeda T, Shundo Y, Hamada N, et al.
Cureus
. 2025 Feb;
17(1):e77645.
PMID: 39968431
complex (MAC) pulmonary disease presents significant therapeutic challenges in respiratory medicine. While amikacin liposome inhalation suspension (ALIS) has emerged as a promising option for treatment-refractory cases, some patients continue to...
3.
Nakashima T, Yanagihara T, Sanai R, Fujimoto Y, Nakao A, Shundo Y, et al.
Cureus
. 2025 Jan;
16(12):e75525.
PMID: 39803058
typically causes mild respiratory infections but can rarely lead to severe complications. We report a case of a 43-year-old immunocompetent male who presented with progressive dyspnea and respiratory failure with...
4.
Koyauchi T, Fujisawa T, Miyashita M, Mori M, Morita T, Yazawa S, et al.
Ann Am Thorac Soc
. 2024 Nov;
22(3):395-402.
PMID: 39513985
Accurate prognostic awareness (PA) and knowledge of the disease are critical for decision-making regarding treatment options, advance care planning, and end-of-life care. However, they have not been investigated in patients...
5.
Ebi N, Inoue H, Fujimoto Y, Chen M, Sanai R, Kushima N, et al.
Transl Lung Cancer Res
. 2024 Nov;
13(10):2573-2584.
PMID: 39507040
Background: Few studies have examined the safety and efficacy of docetaxel/ramucirumab (DOC/RAM) therapy in advanced non-small cell lung cancer (NSCLC) complicated by interstitial lung disease (ILD). Given the potential of...
6.
Sanai R, Yanagihara T, Ikeda T, Koga K, Shundo Y, Hamada N, et al.
Cureus
. 2024 Oct;
16(9):e68364.
PMID: 39360100
SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rare and aggressive malignancy characterized by the loss of SMARCA4 protein expression. It typically affects middle-aged male smokers and has a poor prognosis due...
7.
Sanai R, Hirata T, Yanagihara T, Okamoto M, Ikeda T, Shundo Y, et al.
Cureus
. 2024 Jul;
16(5):e61260.
PMID: 38947622
Platypnea-orthodeoxia syndrome (POS) is a rare condition characterized by dyspnea and oxygen desaturation that worsens in the upright position and improves when lying down. We report the case of a...
8.
Ebi N, Inoue H, Igata F, Okuma R, Kinoshita E, Kawabata T, et al.
Anticancer Res
. 2024 Jun;
44(7):3087-3095.
PMID: 38925810
Background/aim: Nivolumab and ipilimumab combination therapy has been extensively explored for the treatment of advanced non-small-cell lung cancer (NSCLC) through the pivotal phase III trials CheckMate 227 and CheckMate 9LA....
9.
Hirama T, Shundo Y, Watanabe T, Ohsumi A, Watanabe T, Okada Y
Clin Exp Med
. 2024 Jun;
24(1):116.
PMID: 38822907
No abstract available.
10.
Hirama T, Shundo Y, Watanabe T, Ohsumi A, Watanabe T, Okada Y
Clin Exp Med
. 2024 Apr;
24(1):68.
PMID: 38578337
Letermovir, initially approved for cytomegalovirus (CMV) prophylaxis in hematopoietic stem-cell transplantation, has gained attention for off-label use in lung-transplant (LTx) recipients. Given the high susceptibility of LTx recipients to CMV...